Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
Clinical Lymphoma Myeloma and Leukemia · 2025-09 · 25 (9) · e628-e637.e4
DOI: 10.1016/j.clml.2025.04.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025-09. Verfasst von Michael J Slade und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO. Electronic address: sladem@wustl.edu. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasm, Residual, Hematopoietic Stem Cell Transplantation, Mass Spectrometry. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
BACKGROUND: While marrow-based measurable residual disease (MRD) testing for multiple myeloma (MM) is highly associated with outcomes, it is challenging to implement for serial monitoring. Consequently, blood-based MRD testing is desirable. PATIENTS AND METHODS: In this study, we investigated the use of clonotypic mass spectrometry (CT-MS) for blood-based monitoring of M-protein in patients undergoing autologous hematopoietic cell transplant (AHCT). We performed a pilot analysis to assess assay performance, then restricted our analysis of CT-MS as a blood-based MRD assay to patients with 1) banked baseline samples pre-AHCT, 2) no M-protein on serum protein electrophoresis at day +100 post-AHCT and 3) available samples at day +100. RESULTS: One hundred and eleven patients with analyzed, with 94 patients included in the MRD analysis. We derived a proposed threshold for MRD via the minimal P-value approach using two different methods. We found that CT-MS MRD-positivity at day + 100 post-AHCT was significantly associated with worse progression-free survival (PFS) (P < .0001, median PFS 2.5 vs. 8.4 years), with a HR of 3.74 (P = .0002). This association was stable on multi-variable analysis (MVA) adjusting for known risk factors (aHR: 3.68, P = .003). CT-MS MRD-positivity was also associated with significantly worse overall survival (median: 4.95 years vs. not reached, P = .001, HR: 3.95), stable on MVA (aHR: 3.25, P = .01). CONCLUSION: Our study suggests CT-MS may be a useful tool for blood-based MRD in multiple myeloma (MM).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO. Electronic address: sladem@wustl.edu.
- Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO.
- Rapid Novor, Kitchener, Ontario, Canada.
- Division of Laboratory and Genomic Medicine, Department of Pathology, Washington University in Saint Louis, St. Louis, MO.
- Division of Public Health Sciences, Washington University in Saint Louis, St. Louis, MO.
Förderung
- National Cancer Institute
Zitieren
APA
Slade, M. J., Fortier, J., Khaled, A., Fiala, M., McDonald, Z., Zaydman, M. A., Wan, F., Schroeder, M. A., Stockerl-Goldstein, K., Yang, L., & Vij, R. (2025). Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant. Clinical Lymphoma Myeloma and Leukemia, 25(9), e628-e637.e4. https://doi.org/10.1016/j.clml.2025.04.017
Vancouver
Slade MJ, Fortier J, Khaled A, Fiala M, McDonald Z, Zaydman MA, et al. Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant. Clinical Lymphoma Myeloma and Leukemia. 2025;25(9):e628-e637.e4. doi:10.1016/j.clml.2025.04.017
BibTeX
@article{Slade2025,
author = {Slade, Michael J and Fortier, Julie and Khaled, Abir and Fiala, Mark and McDonald, Zac and Zaydman, Mark A and Wan, Fei and Schroeder, Mark A and Stockerl-Goldstein, Keith and Yang, Liqiang and Vij, Ravi},
title = {Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
volume = {25},
number = {9},
pages = {e628--e637.e4},
doi = {10.1016/j.clml.2025.04.017}
}
EUVIMED